Franklin Street Advisors Inc. NC Acquires Shares of 25,000 Five Prime Therapeutics Inc (FPRX)
Franklin Street Advisors Inc. NC acquired a new position in shares of Five Prime Therapeutics Inc (NASDAQ:FPRX) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 25,000 shares of the biotechnology company’s stock, valued at approximately $548,000.
Other large investors have also added to or reduced their stakes in the company. Oppenheimer & Co. Inc. bought a new stake in shares of Five Prime Therapeutics during the third quarter worth $223,000. Dupont Capital Management Corp bought a new stake in shares of Five Prime Therapeutics in the third quarter valued at about $341,000. Legal & General Group Plc raised its holdings in shares of Five Prime Therapeutics by 3.1% in the second quarter. Legal & General Group Plc now owns 9,455 shares of the biotechnology company’s stock valued at $288,000 after acquiring an additional 287 shares in the last quarter. Virtu KCG Holdings LLC bought a new stake in shares of Five Prime Therapeutics in the second quarter valued at about $331,000. Finally, Tudor Investment Corp ET AL raised its holdings in shares of Five Prime Therapeutics by 49.4% in the second quarter. Tudor Investment Corp ET AL now owns 11,999 shares of the biotechnology company’s stock valued at $361,000 after acquiring an additional 3,966 shares in the last quarter. Institutional investors and hedge funds own 83.66% of the company’s stock.
A number of equities analysts have commented on the stock. BidaskClub upgraded shares of Five Prime Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, December 21st. Zacks Investment Research downgraded shares of Five Prime Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, November 9th. ValuEngine downgraded shares of Five Prime Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, November 7th. BMO Capital Markets boosted their target price on shares of Five Prime Therapeutics from $71.00 to $75.00 and gave the stock an “outperform” rating in a report on Tuesday, November 7th. Finally, Royal Bank of Canada boosted their target price on shares of Five Prime Therapeutics from $41.00 to $50.00 and gave the stock an “outperform” rating in a report on Monday, November 6th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $64.00.
In related news, Director William R. Ringo sold 600 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $45.33, for a total value of $27,198.00. Following the sale, the director now owns 600 shares in the company, valued at $27,198. The sale was disclosed in a legal filing with the SEC, which is available through this link. 6.50% of the stock is currently owned by insiders.
Shares of Five Prime Therapeutics Inc (NASDAQ FPRX) traded up $0.30 during mid-day trading on Wednesday, hitting $21.96. The stock had a trading volume of 457,600 shares, compared to its average volume of 417,217. Five Prime Therapeutics Inc has a 1-year low of $19.73 and a 1-year high of $52.72. The stock has a market capitalization of $635.60, a price-to-earnings ratio of -4.33 and a beta of 3.90.
Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($1.54) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.35) by ($0.19). Five Prime Therapeutics had a negative return on equity of 41.57% and a negative net margin of 408.42%. The business had revenue of $8.33 million for the quarter, compared to analysts’ expectations of $16.16 million. During the same quarter in the previous year, the firm posted ($0.72) EPS. Five Prime Therapeutics’s revenue was up 24.7% on a year-over-year basis. equities analysts anticipate that Five Prime Therapeutics Inc will post -5.56 earnings per share for the current year.
Five Prime Therapeutics Profile
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
Want to see what other hedge funds are holding FPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Five Prime Therapeutics Inc (NASDAQ:FPRX).
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.